Single immunoglobulin IL-1 receptor-related protein attenuates the lipopolysaccharide-induced inflammatory response in A549 cells.
The lipopolysaccharide (LPS)-Toll-like receptor 4 (TLR4) signaling pathway in alveolar epithelial cells plays an important role in many pathologic processes such as acute lung injury (ALI). The single immunoglobulin IL-1 receptor-related protein (SIGIRR) is an inhibitor of LPS-TLR4 signaling, but its expression and function in alveolar epithelial cells are still unknown. In this study, we examined the expression of SIGIRR in normal human lung tissue using immunohistochemistry, reverse transcription-PCR (RT-PCR) and Western blot and found that SIGIRR was expressed in alveolar epithelial cells. Treatment of an alveolar epithelial cell line, A549, with LPS and we observed a downregulation of SIGIRR mRNA, which returned to normal levels 24h after LPS exposure. A549 cells were then transfected with a SIGIRR eukaryotic expression vector to over-express SIGIRR or, as a control, with an empty vector. Following LPS exposure, the transcriptional activity of NF-kappaB was measured using a dual-luciferase reporter assay system, and the concentration of IL-1beta, TNF-alpha and IL-6 was determined by ELISA, and cell proliferation was measured by MTT. In A549 cells that over-expressed SIGIRR, LPS treatment resulted in a significant decrease in the transcriptional activity of NF-kappaB and cell growth inhibition ratio, as well as lower levels of secreted IL-1beta, TNF-alpha and IL-6. In conclusion, SIGIRR in A549 cells inhibits the transcriptional activity of NF-kappaB and reduces the amount cytokines produced, protecting these cells from acute LPS-induced damage.
Feng
Tian
T
Department of Thoracic Surgery, Tangdu Hospital, The Forth Military Medical University. Xi'an, Shaanxi, China. tftoyota@yahoo.com.cn
Yunfeng
Ni
N
Jinbo
Zhao
Z
Zhipei
Zhang
Z
Huizhong
Zhang
Z
Li
Liu
L
Tao
Jiang
J
Yunjie
Wang
W
D045744:Cell Line, Tumor; D015536:Down-Regulation; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D016328:NF-kappa B / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000235:genetics / Q000378:metabolism*; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D016328:NF-kappa B; D017472:Receptors, Interleukin-1; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; C546891:SIGIRR protein, human